After analyses of the clinical survival information of melanoma patients with BRAF mutations using TCGA database57, we performed survival analyses that associated the discretized NF2, ITGB3, and IGF1R expression status (higher, high, medium, low, and lower) of every individual patient with overall survivals. This evidence concerns the gene BRAF and melanoma.